Kyverna Therapeutics (KYTX) Income from Continuing Operations (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Income from Continuing Operations came in at 74163000.0 in Q1 2026, down 62.83% YoY from 199529091.97 in Q1 2025, and down 96.55% on a QoQ basis from 37732000.0 in Q4 2025.
Kyverna Therapeutics (KYTX) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Income from Continuing Operations data on file, last reported at 74163000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 62.83% year-over-year to 74163000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 208952000.0 (down 22.46% YoY) and the FY2025 annual result came in at 204554000.0, down 56.97% from the prior year.
- Income from Continuing Operations eased to 74163000.0 in Q1 2026, from 37732000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 11661000.0 in Q1 2023 to a low of 74163000.0 in Q1 2026.
- A 4-year average of 36149384.62 and a median of 40424000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations plunged 203.32% — and 2025, when it gained 6.66%.
- Tracing KYTX's Income from Continuing Operations over 4 years: stood at 20635000.0 in 2023, then tumbled by 95.9% to 40424000.0 in 2024, then grew by 6.66% to 37732000.0 in 2025, then sank by 96.55% to 74163000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 74163000.0 (Q1 2026), 37732000.0 (Q4 2025), and 52850000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | -70.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -70.34 Mn |
| Mar 31, 2026 | -74.16 Mn |
| Dec 31, 2025 | -37.73 Mn |
| Sep 30, 2025 | -52.85 Mn |
| Jun 30, 2025 | -44.21 Mn |
| Mar 31, 2025 | -45.55 Mn |
| Dec 31, 2024 | -40.42 Mn |
| Sep 30, 2024 | -43.29 Mn |
| Jun 30, 2024 | -41.37 Mn |
| Mar 31, 2024 | -28.42 Mn |
| Dec 31, 2023 | -20.64 Mn |
| Sep 30, 2023 | -16.00 Mn |
| Jun 30, 2023 | -13.64 Mn |
| Mar 31, 2023 | -11.66 Mn |